Medtronic gets FDA OK for next-gen glucose monitoring system

The FDA has cleared Medtronic's ($MDT) iPro 2, a next generation professional continuous glucose monitoring system. "My vision is to make an iPro2 evaluation part of routine visits for many of my patients with diabetes. I find it particularly helpful in identifying repeated glucose lows at night and glucose highs after meals, issues that a near-normal A1C does not reveal," said Dr. David Huffman of University Diabetes and Endocrine Consultants. Medtronic release